ANTIBODIES TO B7-H1 AND TO CTLA-4 FOR TREATING NON-SMALL-CELL LUNG CANCER Russian patent published in 2019 - IPC A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a method of treating NSCLC in a human patient comprising administering to patient 20 mg/kg of MEDI4736 or its antigen-binding fragment and 1 mg/kg of tremelimumab or its antigen-binding fragment, where MEDI4736 or its antigen-binding fragment is introduced approximately 1 hour after administration of tremelimumab or its antigen-binding fragment, and where MEDI4736 or its antigen-binding fragment and tremelimumab or its antigen-binding fragment is introduced every 4 weeks for 16 weeks, maximum. Group of inventions also relates to a method of treating NSCLC in a human patient comprising administering to patient 10 mg/kg of MEDI4736 or an antigen-binding fragment thereof and 1 mg/kg of tremelimumab or its antigen-binding fragment; method of treating NSCLC in a human patient comprising administering to patient 15 mg/kg of MEDI4736 or its antigen-binding fragment and 1 mg/kg of tremelimumab or its antigen-binding fragment.

EFFECT: group of inventions provides an optimal balance of safety/effectiveness in the treatment of NSCLC.

36 cl, 37 dwg, 9 tbl, 4 ex